At the recent American College of Cardiology conference, there were several sessions about how cardiologists should view the CV benefits recently discovered in the cardiovascular outcomes trials (CVOTs) of certain diabetes drugs, namely SGLT2 inhibitor Jardiance (Boehringer, LLY) in EMPA-REG and GLP-1 agonist Victoza (NVO) in LEADER, as well as the related GLP-1 agonist semaglutide (NVO) in the smaller SUSTAIN 6 trial. However, there are a number of barriers that prevent cardiologists from prescribing such drugs, including lack of infrastructure to educate and follow up on diabetic patients, as well as concern about infringing on the role of the primary diabetes provider.

We conducted a one-question survey of 15 cardiologists to gauge how CV label changes for such drugs and becoming convinced of their CV benefits would change either their prescribing of these medications or urging primary diabetes providers to do so.

Survey questions and additional resources are listed further below.

If you are a KOL Insight Subscriber, please access the survey from our KOL Insight portal (Subscribers only). Biomedtracker will be offering KOL Reports and Physician Pulse Surveys for purchase a la carte, or access to all reports and surveys can be purchased as a subscription to KOL Insight. For more information on KOL Insight subscription, please email Biomedtracker or call Biomedtracker Client Services at (858) 200-2357. For our disclosures, please read the Biomedtracker Research Standards. Survey Questions:

• Screening question: Recent CVOTs in type 2 diabetes have shown the SGLT-2 inhibitor Jardiance to reduce CV death and the GLP-1 agonist Victoza to reduce MACE (CV death, MI, stroke). Please describe to what extent you currently either prescribe such medications to your patients with diabetes or urge your patients' primary diabetes providers to prescribe them?
• Recent CVOTs in type 2 diabetes have shown the SGLT-2 inhibitor Jardiance to reduce CV death and the GLP-1 agonist Victoza to reduce MACE (CV death, MI, stroke). Assuming both drugs have label indications for their demonstrated CV benefits, and that you are able to be convinced that these drugs provide a substantial CV benefit, please describe to what extent this will lead you to prescribe such medications to your patients with diabetes or urge patients' primary diabetes providers to do so?